Spartan FRX Project Reproducibility Study

Analytical Reproducibility of a Medical Device Clinical Trial

Official title:

Study of the Analytical Reproducibility of the Spartan FRX CYP2C19 *2,*3 and *17 Genotyping System.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01676298
• Other study ID #: 01001686
• Status: Completed
• Phase: N/A
• First received: August 28, 2012
• Last updated: December 3, 2012
• Start date: August 2012
• Est. completion date: November 2012

Study information

• Verified date: December 2012
• Source: Spartan Bioscience Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Spartan Bioscience, Inc.
• Study type: Observational

Clinical Trial Summary

The Spartan FRX CYP2C19 Test System (hereafter referred to as the 'FRX System') is a qualitative in vitro diagnostic test for the identification of a patient's CYP2C19 *2, *3 and *17 genotypes from genomic DNA obtained from buccal swab samples. The objective of the study is to evaluate the performance of the FRX System under multivariate conditions including different days, sites, operators and systems.

Description:

The FRX system is comprised of hardware and consumable components. The hardware components of the system include an Analyzer (thermal cycler with fluorescence detection capability), a notebook computer and a printer. The consumable component of the FRX system is a sample collection kit. Each kit contains a buccal swab (used to collect the patient sample) and a tube containing the reagents required for genomic DNA extraction and PCR (polymerase chain reaction) amplification stages of the test.

The Spartan FRX System is capable of detecting three CYP2C19 SNPs(single nucleotide polymorphism) (*2, *3, *17) in each test performed. An individual sample collection kit is required for each SNP tested; therefore three sample collection kits are required for each test performed on the system.

To perform a test, the user collects three buccal samples from the patient and then inserts a sample into each of the three reagent tubes (one for each of the CYP2C19 loci *2, *3 and *17). The reagent tubes are placed into the Analyzer and the FRX system automates the processes of DNA extraction, PCR amplification, fluorescent signal detection and data analysis. The system provides the user with a printed result listing the patient genotypes at the *2, *3 and *17 loci.

The objective of the study is to evaluate the performance of the FRX System under multivariate conditions. Specifically, the following variables will be included in the study:

• Test site - x3

• Operator - x6 (2 per site)

• Day - x15 (5 non-consecutive days per site)

• FRX System - x16

Test performance is defined as the number of correct genotype calls, expressed as a percentage of the total number of tests performed on the system.

For both the first-pass and second-pass results, 1-sided 95% confidence lower limits will be calculated using the score method for the % correct calls (i.e. % agreement).

Genotype results from the FRX system will be compared with results of DNA sequencing. The result of the FRX System test will be determined to be correct if the genotype calls for all three SNPs are identical to the genotypes determined by DNA sequencing for that sample/individual.

Results of the Reproducibility Study will be acceptable if the lower bound of a 1-sided 95% confidence limit of the total correct call rate per genotype is greater than or equal to 95%, based on second-pass results.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: November 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Above 16 years of age

• Must have required genotype

Exclusion Criteria:

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Analytical Reproducibility of a Medical Device

Intervention

Device:
• Spartan FRX CYP2C19 Test System

Locations

Country	Name	City	State
Canada	Children's Hospital of Eastern Ontario	Ottawa	Ontario
Canada	Ottawa Hospital Research Institute	Ottawa	Ontario
Canada	Mount Sinai Services	Toronto	Ontario

Sponsors (4)

Lead Sponsor	Collaborator
Spartan Bioscience Inc.	Children's Hospital of Eastern Ontario, Mount Sinai Hospital, Canada, Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Correct Calls to Assess Reproducibility of the Spartan FRX CYP2C19 System.	Reproducibility was calculated as a percentage of the correct calls over the total calls made for each genotype group. All calls were made using the Spartan FRX CYP2C19 genotyping diagnostic system.; All data analyses was qualitative, based on the genotype calls determined by the FRX system (using on-board automated data analysis). A printed result listing the genotype call for each SNP was generated by the FRX system at the end of each run. If the result of a test is "Inconclusive" for one or more SNPs, the test were immediately repeated for the corresponding SNP(s) only, per the instructions for use. Results are reported based on both first-pass and second-pass (i.e. repeated test). For both the first-pass and second-pass results, 1-sided 95% confidence lower limits were calculated using the score method for the % correct calls (i.e. % agreement).	After second pass result is complete (~3h)	No